Phase Ia/Ib Study of Afatinib with Capecitabine in Patients with Refractory Solid Tumors and Pancreaticobiliary Cancers
Sign Up to like & getrecommendations! Published in 2025 at "Cancers"
DOI: 10.3390/cancers17111830
Abstract: Simple Summary The epidermal growth factor receptor (EGFR) is overactive in many solid tumors. Afatinib, an EGFR/HER2/HER3 inhibitor, synergizes with capecitabine in preclinical models. This phase Ia/Ib trial evaluated the safety and preliminary efficacy of… read more here.
Keywords: phase study; afatinib capecitabine; solid tumors; study afatinib ... See more keywords